General Information
Drug ID
DR01365
Drug Name
ABT-263
Synonyms
Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
Drug Type
Small molecular drug
Indication Myelofibrosis [ICD11: 2A20.2] Phase 2 [1]
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24978538"></iframe>
3D MOL 2D MOL
Formula
C47H55ClF3N5O6S3
Canonical SMILES
CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
InChI
InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
InChIKey
JLYAXFNOILIKPP-KXQOOQHDSA-N
CAS Number
CAS 119229-65-1
Pharmaceutical Properties Molecular Weight 974.6 Topological Polar Surface Area 170
Heavy Atom Count 65 Rotatable Bond Count 16
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 14
PubChem CID
24978538
PubChem SID
56311703 , 56314453 , 57304426 , 57504587 , 87219189 , 87457108 , 96099448 , 99003698 , 99245529 , 99246089 , 99431767 , 99460835 , 103640740 , 104115920 , 124756924 , 124899202 , 124899203 , 125163731 , 126583646 , 126667000 , 126724167 , 131465096 , 131465716 , 134221945 , 135263748 , 135626669 , 135727392 , 136920253 , 137126833 , 141663047 , 143499177 , 152035716 , 152164573 , 152240012 , 152258081 , 152344157 , 160646920 , 162011689 , 162037376 , 162202714 , 163123180 , 163821637 , 164194132 , 164831796 , 174007035 , 174531509 , 198955115 , 204380851 , 223388517 , 223685382
ChEBI ID
CHEBI:94128
TTD Drug ID
D06ETI
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 ClinicalTrials.gov (NCT03222609) A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis
2 The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.